Socio-Demographic Profile and Prevalence of Tuberculosis (TB) Treatment Outcomes among Tuberculosis/Human Immunodeficiency Virus (TB/HIV) Co-Infected Patients in Kelantan

被引:0
|
作者
Nor, Siti Romaino Mohd [1 ,2 ]
Husin, Mohd Rozi [3 ]
Jaeb, Mat Zuki Mat [4 ]
Naing, Nyi Nyi [1 ]
机构
[1] Univ Sultan Zainal Abidin, Fac Med, Med Campus,Jalan Sultan Mahmud, Kuala Terengganu 20400, Terengganu, Malaysia
[2] Hosp Raja Perempuan Zainab II, Clin Res Ctr Kelantan, Kota Baharu 15586, Kelantan, Malaysia
[3] Jabatan Kesihatan Negeri Kelantan, TB Leprosy Sect, Kota Baharu 15200, Kelantan, Malaysia
[4] Hosp Raja Perempuan Zainab II, Dept Med, Resp Unit, Kota Baharu 15586, Kelantan, Malaysia
来源
PERTANIKA JOURNAL OF SCIENCE AND TECHNOLOGY | 2021年 / 29卷 / 04期
关键词
Co-infected patients; Human Immunodeficiency Virus; HIV; prevalence; socio-demographic; Tuberculosis; TB; PREDICTORS;
D O I
10.47836/pjst.29.4.03
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
In Kelantan, the prevalence of Tuberculosis (TB) treatment success rate among TB/HIV co-infection is still below the success target of the World Health Organisation (WHO). Our objective was to assess the socio-demographic profile and determine the prevalence of TB treatment outcomes among TB/HIV co-infected patients in Kelantan. The crosssectional study involved secondary data from the MyTB online system from January 2014 to December 2018, carried out at TB/Leprosy Sector, State Health Department of Kelantan. The data were analysed using SPSS version 25.0 and STATA version 14. The ethics approval was obtained from the UniSZA Human Research Ethics Committee (UHREC) and Medical Research Ethics Committee (MREC) of Ministry of Health (MOH). There were 6,313 TB cases in Kelantan. Of these, 703 (11.1%) cases were TB/HIV co-infection. However, 36 cases were excluded, and 667 cases were evaluated based on inclusion and exclusion criteria. The mean (SD) age was 38.7 (7.9) years, and the mean duration of TB treatment was 202.8 (131.27) days. The prevalence of successful treatment was 57.1%, with 19.8% cases were cured, and another 37.3% cases were completed treatment. While the unsuccessful were 42.9%, with 10.1% cases were defaulted, and 32.8% cases died. The successful outcomes were significantly associated with the educational level, the anatomy of TB location, smoking status, DOTS by health care providers, source of notification, the place of treatment and method of detection. This study provides the basic data of patient's socio-demographic profiles, and the prevalence of TB treatment success in Kelantan is under international target by WHO of >= 90.0%.
引用
收藏
页码:2279 / 2293
页数:15
相关论文
共 50 条
  • [21] Virologic and immunologic outcome of HAART in Human Immunodeficiency Virus (HIV)-1 infected patients with and without tuberculosis (TB) and latent TB infection (LTBI) in Addis Ababa, Ethiopia
    Kassa, Desta
    Gebremichael, Gebremedhin
    Alemayehu, Yodit
    Wolday, Dawit
    Messele, Tsehaynesh
    van Baarle, Debbie
    AIDS RESEARCH AND THERAPY, 2013, 10
  • [22] The prevalence and associated factors for delayed presentation for HIV care among tuberculosis/HIV co-infected patients in Southwest Ethiopia: a retrospective observational cohort
    Gesesew, Hailay
    Tsehaineh, Birtukan
    Massa, Desalegn
    Tesfay, Amanuel
    Kahsay, Hafte
    Mwanri, Lillian
    INFECTIOUS DISEASES OF POVERTY, 2016, 5
  • [23] The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis
    Tanuja N. Gengiah
    Nicholas H. G. Holford
    Julia H. Botha
    Andrew L. Gray
    Kogieleum Naidoo
    Salim S. Abdool Karim
    European Journal of Clinical Pharmacology, 2012, 68 : 689 - 695
  • [24] The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis
    Gengiah, Tanuja N.
    Holford, Nicholas H. G.
    Botha, Julia H.
    Gray, Andrew L.
    Naidoo, Kogieleum
    Karim, Salim S. Abdool
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (05) : 689 - 695
  • [25] Proportion of Multidrug-Resistant Tuberculosis in Human Immunodeficiency Virus/Mycobacterium tuberculosis Co-Infected Patients in Korea
    Joh, Joon Sung
    Hong, H. Christian
    Jeong, In A.
    Chin, Bum Sik
    Yang, Hye Jin
    Choi, Hongjo
    Bang, Ji Hwan
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2012, 27 (10) : 1143 - 1146
  • [26] Treatment Outcomes of Tuberculosis and Associated Factors Among Tuberculosis and Human Immunodeficiency Virus Co-infected Patients in Public Health Facilities in Jigjiga, Somali Region, Ethiopia
    Abdilahi, Abdilahi Omer
    Ahmed, Ayan Abdishukri
    Osman, Mohamed Omar
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (03)
  • [27] The prevalence of human immunodeficiency virus infection among TB patients in Port Harcourt Nigeria
    Erhabor, O.
    Jeremiah, Z. A.
    Adias, T. C.
    Okere, C. E.
    HIV AIDS-RESEARCH AND PALLIATIVE CARE, 2010, 2 : 1 - 5
  • [28] Quality of life among tuberculosis (TB), TB retreatment and/or TB-HIV co-infected primary public health care patients in three districts in South Africa
    Louw, Julia
    Peltzer, Karl
    Naidoo, Pamela
    Matseke, Gladys
    Mchunu, Gugu
    Tutshana, Bomkazi
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2012, 10
  • [29] Drug provocation test: a diagnostic approach to drug hypersensitivity reaction in tuberculosis (TB)-human immunodefficiency virus (HIV) co-infected patient
    Mawar, N.
    Soetikno, V.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2015, 45 : S106 - S106
  • [30] Improving Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) Treatment Monitoring in South Africa: Evaluation of an Advanced TB/HIV Course for Healthcare Workers
    Galagan, Sean
    Jed, Suzanne
    Sumitani, Jeri
    Gilvydis, Jennifer M.
    Bakor, Albert
    Cooke, Richard
    Naidoo, Evasen
    Winters, Debra
    Weaver, Marcia R.
    OPEN FORUM INFECTIOUS DISEASES, 2017, 4 (01):